While conventional therapies for inflammatory bowel disease (IBD) primarily focus on modulating pro-inflammatory cytokines such as TNF-α, emerging evidence highlights the involvement of glucagon-like peptide-1 (GLP-1)—an incretin hormone with anti-inflammatory and cytoprotective properties—in the pathogenesis and potential treatment of IBD [41,42]. This evidence concerns the gene GLP1R and inflammatory bowel disease.